Skip to main content

When Hope Meets Reality

Willing to pay any price for a “chance”?
Doctors should explain treatment and testing more clearly and carefully.

More than 700 people filed six class-action lawsuits across five U.S. states against companies offering PGT-A testing — accusing them of selling false hope.

A global survey of 151 IVF clinics found that 83% use PGT-A testing:

  • Europe: 32%
  • USA & Canada: 29%

Common reasons include:

  • Older age (77%)
  • Repeated implantation failure (70%)
  • Unexplained miscarriages (65%)

20% of clinics transferred embryos labeled “abnormal” — mostly in the USA (56%). Nearly half (49.3%) of those resulted in a pregnancy or baby.

ESHRE, HFEA, and ASRM do NOT recommend the routine use of PGT-A.

Yet PGT-A is often offered as routine to women over 35 or those with previous IVF failure — effectively covering 90% of IVF patients. Each case should be carefully evaluated — medically, emotionally, and financially.

Rapid Growth in PGT-A Use (USA)

2016: 11.4%
2017: 21.4%
2019: 44%

The use of PGT-A more than tripled in three years — showing how quickly and often uncritically it became widespread in IVF treatment.

Sources:

  • Klein, A. (2025, March 7). Pricey IVF Test May Be Selling False Hope. Truthdig.
  • Gleicher, N. et al. (2019). Preimplantation genetic testing for aneuploidy (PGT-A). Journal of Assisted Reproduction and Genetics, 36(1), 29–37.
www.aboutivf.com | Evidence-based IVF resources

This material is for informational purposes only – always consult your doctor before making any decisions.